Protiva Biotherapeutics
Biotechnology company developing nucleic acid based pharmaceutical products
About Protiva Biotherapeutics
Protiva Biotherapeutics Inc. operated as a development-stage biotechnology company, carving a niche in the creation of nucleic acid-based pharmaceutical products. Founded in 2000 and headquartered in Burnaby, Canada, the firm was strategically focused on developing treatments for a range of human diseases, including cancer and various infectious diseases.
The company was spun out of Inex Pharmaceuticals Corp. in 2001. Dr. Mark J. Murray, a biochemist and seasoned biotech executive, served as President and CEO, while biochemist Ian MacLachlan, who came from Inex, was the Chief Scientific Officer. MacLachlan's team was instrumental in pioneering and advancing a critical drug delivery technology. This technology centered on a proprietary platform known as Stable Nucleic Acid-Lipid Particles (SNALP), which enables the effective encapsulation and delivery of nucleic acid-based drugs, such as small interfering RNA (siRNA), to targeted sites of disease. The ability to silence specific genes that cause disease positioned Protiva at the forefront of RNA interference (RNAi) therapeutics.
Protiva's business model revolved around both internal product development and strategic partnerships. The company established license agreements and research collaborations with major pharmaceutical entities, including Alnylam Pharmaceuticals, Merck, and Roche. These collaborations provided access to Protiva's delivery technology for the development of RNAi therapeutics, with Protiva eligible to receive milestone payments and royalties on product sales. Revenue was generated through these partnerships and research agreements. In March 2008, after a period of litigation over intellectual property, Protiva announced a significant business combination with Tekmira Pharmaceuticals Corporation. The merger, completed in June 2008, saw Tekmira acquire all of Protiva's outstanding equity, making Protiva a wholly-owned subsidiary. The combined entity, retaining the Tekmira name, aimed to become a global leader in RNAi therapeutics, consolidating the intellectual property and research teams of both Vancouver-based companies. Dr. Murray became the President and CEO of the new Tekmira, and Dr. MacLachlan took on the role of Chief Scientific Officer.
Source: Dealroom company dataNews
Open roles
Protiva Biotherapeutics in the Seattle ecosystem
The Protiva Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Lumira Ventures
GrowthWorks Capital
Kinetic Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Protiva Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Protiva Biotherapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


